Bayer (BAYRY) announced that its MEDRAD Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package presentations for Ultravist, Isovue, Optiray and Omnipaque. Additionally, Bayer announced the addition of Visipaque in single-dose vials as Centargo’s fifth compatible contrast agent. This expansion now offers customers in high-throughput imaging suites a wider range of compatible contrast agents and presentations from Centargo.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Dare Bioscience announces return of rights to Oveprene
- Bayer data could ‘somewhat renew’ optimism for Bristol drug, says Morgan Stanley
- Video: Biogen up after Novo weight-loss drug fails to slow Alzheimer’s progress
- Bayer’s Asundexian met primary efficacy, safety endpoints in Phase III study
- Bayer announces FDA approval of Hyrnuo for non-small cell lung cancer